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Introduction
Despite their limited licensed indications, anti-IL1
agents are often used in real-life practice for an increas-
ing number of diseases. A national survey to record
their off-label use in France was started in January
2011. The survey is coordinated by the French National
Reference Centre for Auto-inflammatory Diseases,
under the aegis of the “Club Rhumatisme et Inflamma-
tion” (CRI).
Objectives
The survey aims to gather information concerning: the
number of patients treated with anti-IL1 agents in
France, the treated disease, the kind and the indication
of the used anti-IL1 agents, their efficacy and safety.
Methods
We set up a physician-directed questionnaire available
on the website of CRI since January 2011, covering the
following areas: patient data, disease data, anti-IL1
agent, its efficacy, adverse events. We advertised the
study on the occasion of French and European rheuma-
tology congresses and by e-mail to French physicians
that could be interested. Any adult or paediatric patient
who had received an anti-IL1 agent after January 2005
in France could be included after medical informed
consent.
Results
At two years 188 patients (99males, 88 females, mean
age 35.2 years), from 37 centres have been included.
Main diseases were: adult onset Still’s disease (AoSD)
(35), systemic onset juvenile idiopathic arthritis (SoJIA)
(29), gout (26), anakinra-treated cryopirin associated
periodic syndrome (CAPS) (21), mevalonate kinase defi-
ciency (MKD) (14), familial Mediterranean fever (FMF)
(12), SAPHO syndrome (9), Schnitzler’s syndrome (7).
The main off-label used agent was anakinra, used at
least once in 182 patients. Canakinumab was used in 23
patients. Rilonacept is not yet available in France. Ana-
kinra shows partial to complete efficacy in most patients
(90%); complete clinical response rates vary according to
specific diseases, being higher in Schnitlzler’s syndrome,
gout, CAPS, AoSD and SoJIA. Fifty four percent of
patients showed at least one adverse event (AE), mainly
minor injection site reactions, and some showed a ser-
ious AE (SAE), mainly severe infection. Preliminary data
of our survey suggest that canakinumab was generally
well tolerated, without any SAE.
Conclusion
Two-year results of the survey confirm the wide use of
anti-IL1 agents in clinical practice. The main off-label
used agent was anakinra, which showed efficacy in the
vast majority of patients. Patients with Schnitlzler’s syn-
drome, gout, CAPS and AoSD showed the higher com-
plete clinical response rate. A sizeable number of
adverse events, namely injection site reactions, was
reported in patients treated by anakinra, Canakinumab
was generally well tolerated, without any SAE. The
number of patients treated by canakinumab was too
small to evaluate its efficacy.
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